Cholesterol-lowering treatment of patients with chronic heart failure after heart transplantation
https://doi.org/10.51922/2616-633X.2022.6.1.1485
Abstract
This scientific review is devoted to the assessment of the role and effects of statin therapy in the treatment of patients with heart failure (HF). The article overviews the possibilities of using new medications with a profound lipid-lowering effect in patients with HF, belonging to the class of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9). The results of our own research are also presented, the purpose of which was to study the association of statin therapy with the state of the coronary arteries (CA) in the long-term period after heart transplantation (HT).
Materials and methods. The data of 75 patients after HT were analyzed. Coronary angiography and intravascular ultrasound were performed to assess coronary artery (CA) damage. The degree of coronary artery disease was determined according to the Stanford classification. In the dynamics of observation, biochemical parameters of blood were assessed.
Results and discussion. 7 years (84 months) after HT, patients were divided in 3 groups: 1st with no significant damage to the coronary arteries (n = 38); 2nd with significant damage to the CA (n = 20); 3rd with angiographically significant stenosis of the coronary artery (n = 17). Within 12 months after HT, the groups were comparable in terms of the dose of atorvastatin taken by patients (from 5 to 20 mg). By the 12th month of therapy, the median dose of the medication was significantly lower (5 (5; 10) mg) in group 3 than in groups 1 (20 (10; 40) mg, p = 0.046) and 2 (20 (20; 40) mg, p = 0.008). The dose reduction of the lipid-lowering drug was due to a decrease in the concentration of LDL-C. After 36 months there was a steady increase in the level of LDL-C cholesterol in the blood in group 3. In groups 1 and 2, there were no significant fluctuations in the concentration of LDL cholesterol within the period from 6 to 84 months after HT.
Conclusions. In order to prevent the development and progression of coronary artery disease in the long-term period after HT, more aggressive statin therapy is required (at least 20 mg of atorvastatin, even after reaching the target LDL-C level). For patients at high risk of developing coronary heart disease and intolerant to more traditional lipid-lowering treatments, PCSK9 should be considered as a promising alternative.
About the Author
A. K. Kurlianskaya
Republican Scientific and Practical Centre of Cardiology
Belarus
Belarus
Minsk
References
1. Huffman M.D., Berry J.D., Ning H., Dyer A.R., Garside D.B., Cai X., Daviglus M.L., Lloyd-Jones D.M. Lifetime risk for heart failure among white and black Americans: Cardiovascular lifetime risk pooling project. J Am Coll Cardiol, 2013, vol. 61(14), pp. 1510-1517.
2. Rosenson R.S., Hegele R.A., Fazio S., Cannon C.P. The evolving future of PCSK9 Inhibitors. J Am Coll Cardiol, 2018, vol. 72, pp. 314-329.
3. Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckert E., Hegele R.A., Krauss R.M. [et al.] Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel. Eur Heart J, 2017, vol. 38, pp. 2459-2472.
4. Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S. [et al.] 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol, 2019, vol. 73, pp. e285-350.
5. Authors/Task Force Members, ESC committee for practice guidelines (CPG), ESC national cardiac societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, vol. 290, pp. 140-205.
6. Brown M.S., Goldstein J.L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res, 1980, vol. 21(5), pp. 505-517.
7. Jiang S.Y., Li H., Tang J.J., Wang J., Luo J., Liu B., Wang J.-K., Shi X.-J., Cui H.-W., Tang J., Yang F., Qi W., Qiu W.-W., Song B.-L. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nat Commun, 2018, vol. 9(1), pp. 5138.
8. Delahoy P.J., Magliano D.J., Webb K., Grobler M., Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clin. Ther, 2009, vol. 31(2), pp. 236-244.
9. Kazi D.S., Penko J.M., Bibbins-Domingo K. Statins for primary prevention of cardiovascular disease: Review of evidence and recommendations for clinical practice. Med Clin North Am, 2017, vol. 101(4), pp. 689-699.
10. Logue J. AL-Ghibiwi H., Alamri A.A., Preiss D. Systematic review of studies exploring reasons for statin non-adherence and of randomized controlled trials of interventions to improve adherence. Atherosclerosis, 2015, vol. 241(1), pp. e52.
11. Bielecka-Dabrowa A., Goch J.H., Mikhailidis D.P., Rysz J., Maciejewski M., Banach M. the influence of atorvastation on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit, 2009, vol. 5(12), pp. 12.
12. Mozaffarian D., Nye R., Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol, 2004, vol. 93(9), pp. 1124-1129.
13. Gastelurrutia P., Lupón J., de Antonio M., Urrutia A., Díez C., Coll R., Altimir S., Bayes-Genis A. Statins in heart failure: The paradox between large randomized clinical trials and real life. Mayo Clin Proc, 2012, vol. 87(6), pp. 555-560.
14. Lipinski M.J., Cauthen C.A., Biondi-Zoccai G.G., Abbate A., Vrtovec B., Khan B.V., Vetrovec G.W. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol, 2009, vol. 104(12), pp. 1708-1716.
15. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G.F., Cornel J.H., Dunselman P. [et al.] Rosuvastatin in older patients with systolic heart failure. N Engl J Med, 2007, vol. 357(22), pp. 2248-2261.
16. Bonsu K.O., Reidpath D.D., Kadirvelu A. effects of statin treatment on inflammation and cardiac function in heart failure: An adjusted indirect comparison meta-analysis of randomized trials. Cardiovasc Ther, 2015, vol. 33(6), pp. 338-346.
17. Florkowski C.M., Molyneux S.L., George P.M. Rosuvastatin in older patients with systolic heart failure. N Engl J Med, 2008, vol. 358, pp. 1301.
18. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, 2008, vol. 372, pp. 1231-1239.
19. Bayes-Genis A., Núñez J., Zannad F., Ferreira J.P., Anker S.D., Cleland J.G., Dickstein K., Filippatos G., Lang C., Ng L.L., Ponikowski P., Samani N.J., van Veldhuisen D.J., Zwinderman A.H., Metra M., Lupón J., Voors A.A. The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. J Am Coll Cardiol, 2017, vol. 70, pp. 2128-2136.
20. Tang Z., Jiang L., Peng J., Ren Z., Wei D., Wu C., Pan L., Jiang Z., Liu L. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. Int J Mol Med, 2012, vol. 30, pp. 931-938.
21. Stulak J.M., Davis M.E., Haglund N., Dunlay S., Cowger J., Shah P., Pagani F.D., Aaronson K.D., Maltais S. Adverse events in contemporary continuous-flow left ventricular assist devices: A multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg, 2016, vol. 151, pp. 177-189.
22. Mehra M.R., Uriel N., Naka Y., Cleveland Jr J.C., Yuzefpolskaya M., Salerno C.T., Walsh M.N., Milano C.A. [et al.] A fully magnetically levitated left ventricular assist device-final report. N Engl J Med, 2019, vol. 380, pp. 1618-1627.
23. Vieira J.L., Pfeffer M., Claggett B.L., Stewart G.C., Givertz M.M., Coakley L., Mallidi H.R., Mehra M.R. The impact of statin therapy on neurological events following left ventricular assist system implantation in advanced heart failure. J Heart Lung Transplant, 2020, vol. 39, pp. 582-592.
24. Costanzo M.R., Dipchand A., Starling R., Anderson A., Chan M., Desai S., Fedson S., Fisher P. [et al.] International society of heart and lung transplantation guidelines. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant, 2010, vol. 29, pp. 914-956.
25. Lu W.H., Palatnik K., Fishbein G.A., Lai C., Levi D.S., Perens G., Alejos J., Kobashigawa J., Fishbein M.C. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant, 2011, vol. 30, pp. 1044-1050.
26. Lund L.H., Edwards L.B., Dipchand A.I., Goldfarb S., Kucheryavaya A.Y., Levvey B.J., Meiser B., Rossano J.W., Yusen R.D., Stehlik J. The registry of the International society for heart and lung transplantation. The registry of the international society for heart and lung transplantation: thirty-third adult heart transplantation report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant, 2016, vol. 35, pp. 1158-1169.
27. Kühl M., Binner C., Jozwiak J., Fischer J., Hahn J., Addas A., Dinov B., Garbade J., Hindricks G., Borger M. Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. PLoS One, 2019, vol. 14, pp. e0210373.
28. Moayedi Y., Kozuszko S., Knowles J.W., Knowles J.W., Chih S., Oro G., Lee R., Fearon W.F., Ross H.J., Teuteberg J.J., Khush K.K. Safety and efficacy of PCSK9 inhibitors after heart transplantation. Can J Cardiol, 2019, vol. 35, pp. e1-104.
29. Toth P.P., Descamps O., Genest J., Genest J., Sattar N., Preiss D., Dent R., Djedjos C., Wu Y., Geller M., Uhart M., Somaratne R., Wasserman S.M; PROFICIO investigators. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation, 2017, vol. 135, pp. 1819-1831.
30. Warden B.A., Kaufman T., Minnier J., Duell P.B., Fazio S., Shapiro M.D. Use of PCSK9 inhibitors in solid organ transplantation recipients. JACC Case Reports, 2020, vol. 2, pp. 396-399.
31. Del Val Groba-Marco M., Del Castillo-García S., Barge-Caballero G., Barge-Caballero E., Couto-Mallón D., Crespo-Leiro M.G. Treatment of Hypercholesterolemia With PCSK9 inhibitors in heart transplant recipients. First experience in Spain. Rev Esp Cardiol (Engl Ed), 2019, vol. 72(12), pp. 1084-1086.
32. Jennings D.L., Jackson R., Farr M. PCSK9 inhibitor use in heart transplant recipients: a case series and review of the literature. Transplantation, 2020, vol. 104, pp. e38-39.
33. Broch K., Gude E., Karason K., Dellgren G., Rådegran G., Gjesdal G., Gustafsson F., Eiskjaer H., Lommi J., Pentikäinen M., Lemström K.B., Andreassen A.K., Gullestad L. Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: design of the randomized controlled EVOLVD trial. Clin Transplant, 2020, vol. 34(9), pp. e13984.
34. Fearon W. National Institute of Health, US National Library of Medicine, clinicaltrials. gov. PCSK9 Inhibition After Heart Transplantation [electronic resource]. Available from: https://clinicaltrials.gov/ct2/show/NCT03537742. [Last accessed on 9 Dec 2020].
Review
For citations:
Kurlianskaya A.K. Cholesterol-lowering treatment of patients with chronic heart failure after heart transplantation. Emergency Cardiology and Cardiovascular Risks journal. 2022;6(1):1485-1491. (In Russ.) https://doi.org/10.51922/2616-633X.2022.6.1.1485
Views:
5
Email this article 